Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 6632446
Coating substrates by polymerizing macromers having free radical-polymerizable substituents
expired -
US 6630170
Mesoporous compositions and method of preparation
expired -
US 6630344
Diminishing viral gene expression by promoter replacement
expired -
US 6630447
Peptide inhibitors of LFA-1/ICAM-1 interaction
expired -
US 6630484
6-and 7-substituted analogs of swainsonine their preparation and therapeutic use
expired -
US 6630516
Methods and compositions for preventing and treating chronological aging in human skin
expired -
US 6630121
Supercritical fluid-assisted nebulization and bubble drying
expired -
US 6630572
Thrombin derived polypeptides: compositions and methods for use
expired -
US 6627619
Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
expired -
US 6627731
Thrombin derived polypeptides; compositions and methods for use
expired -
US 6627189
Inhibition of cellular proliferation using ras antisense molecules
expired -
US 6627615
Methods and compositions for in vivo gene therapy
expired -
US 6623738
Semaphorin receptors
expired -
US 6624141
Protamine fragment compositions and methods of use
expired -
US 6623938
I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
expired -
US 6623957
Secretion of T cell receptor fragments from recombinant host cells
expired -
US 6620808
Endocrine modulation with positive modulators of AMPA type glutamate receptors
expired -
US 6620795
Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
expired -
US 6620911
Anti-cryptococcal peptides
expired -
US 6617331
Purine inhibitors of protein kinases, G proteins and polymerases
expired -
US 6617441
Diagnostic test for borrelia infection
expired -
US 6617110
Cells immortalized with telomerase reverse transcriptase for use in drug screening
expired -
US 6613751
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
expired -
US 6613757
COMBINATION OF PROSTACYCLIN WITH AN ESTROGEN OR PROGESTIN FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC VASCULAR DISEASE INCLUDING PREECLAMPSIA AND FOR THE TREATMENT OF HYPERTENSION, AND FOR HORMONE REPLACEMENT THERAPY
expired -
US 6613305
Radionuclide labeling of vitamin B12 and coenzymes thereof
expired -
US 6610906
Nucleotide sequences for gene regulation and methods of use thereof
expired -
US 6610661
Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
expired -
US 6610505
Oncoprotein protein kinase
expired -
US 6610334
Use of thiol redox proteins for reducing protein intramolecular disulfide bonds, for improving the quality of cereal products, dough and baked goods and for inactivating snake, bee and scorpion toxins
expired -
US 6608026
Apoptotic compounds
expired -
US 6605274
Method for in vivo regulation of cardiac muscle contractility
expired -
US 6605282
Multi-subtype FIV vaccines
expired -
US 6605460
Avian pneumovirus vaccine
expired -
US 6602672
Recombinant construct encoding epitope tagged PrP protein
expired -
US 6602680
Production of gabaergic cells
expired -
US 6602975
Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
expired -
US 6599275
Implantable medical device
expired -
US 6599502
Intracellular delivery vehicles
expired -
US 6599873
Interleukin-1 inhibitors, compositions, and methods of treatment
expired -
US 6599510
Abundant extracellular products and methods for their production and use
expired -
US 6599495
Nucleotide and protein sequence of mammastatin and methods of use
expired -
US 6599744
Viral expression vectors comprising a ribosomal promoter sequence
expired -
US 6599726
Compositions and methods comprising cytostatic protein kinase
expired -
US 6600021
Use of thiol redox proteins for reducing protein intramolecular disulfide bonds, for improving the quality of cereal products, dough and baked goods and for inactivating snake, bee and scorpion toxins
expired -
US 6596762
Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
expired -
US 6596296
Drug releasing biodegradable fiber implant
expired -
US 6596310
Method of artificial insemination by timed release of sperm from capsules or solid beads
expired -
US 6596705
Inhibition of L-selectin and P-selection mediated binding using heparin
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory